gbio: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by (used in) investing activities	43,436	17,908
Proceeds from exercise of stock options and espp, net	81	81
Tax withholding payments related to net share settlements of restricted stock units	10	8
Net cash used in financing activities	71	73
Net decrease in cash, cash equivalents and restricted cash	-54,361	-27,207
Cash and cash equivalents at beginning of period	78,453	-
Cash and cash equivalents at end of period	24,092	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net cash provided by (used in) investing activities	43,436	17,908
Proceeds from exercise of stock options and espp, net	81	81
Tax withholding payments related to net share settlements of restricted stock units	10	8
Net cash used in financing activities	71	73
Net decrease in cash, cash equivalents and restricted cash	-54,361	-27,207
Cash and cash equivalents at beginning of period	78,453	-
Cash and cash equivalents at end of period	24,092	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)